Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Research



Comparison of safety and cost-effectiveness of topical 5% permethrin and topical 1% ivermectin in patients of uncomplicated scabies

Baswaraj Munge, Haritha Bodusu, Narendar Koyagura, Prasanna Vedula.

Abstract
Background: Scabies is an infestation of the skin by the mite Sarcoptes scabiei that causes a pruritic skin eruption. Scabies is a relatively common infestation that can affect individuals of any age and socioeconomic status. The worldwide prevalence is estimated to be 100 million people, with wide variation in prevalence among individual geographic regions.Worldwide, an estimated 300 million cases occur annually.The burden of the disease is highest in developing countries where the disease is endemic. Many studies were conducted on scabies using different therapies to compare the efficacy. However, only some studies were conducted by comparing the safety and cost-effectiveness. Our country is a developing country. Hence, cost is an essential factor in the individual and public health sector.

Aims and Objectives: This study aims to provide better and improved treatment options for scabies based on efficacy, safety, and cost-effectiveness profile with objective to compare the efficacy, cost-effectiveness, and safety profile of 5% permethrin and 1% ivermectin in uncomplicated scabies patients.

Materials and Methods: This was a randomized, prospective, open-label, comparative, parallel study. After taking Institutional Ethics Committee permission, the study was conducted from May 2019 to June 2019, on 95 patients who came to RVMIMS hospital dermatology outpatient department, Laxmakkapally, Mulugu Mandal, Siddipet district in Telangana state, and diagnosed scabies is randomly allocated to two groups. One group received permethrin 5% cream as a single application, and the other group received ivermectin 1% lotion as a single application.

Results:A total of 93 patients were enrolled in the study and randomly allocated into two treatment groups, permethrin group having 48 patients and ivermectin group having 45 patients.

Conclusion: Although topical 5% permethrin is as effective as topical 1% ivermectin, permethrin is considered as superior drug compared to topical ivermectin regarding safety andcost-effectiveness. There were two dropouts of patients during the study in ivermectin intervention. At the end of the study, we concluded that topical 5% permethrin is safer and cost-effective drug compared to topical 1%ivermectin.

Key words: Scabies; Permethrin; Ivermectin



Similar Articles

Integrated Tick Management in South Central Wisconsin: Impact of Invasive Vegetation Removal and Host-Targeted Acaricides on the Density of Questing Ixodes scapularis (Acari: Ixodidae) Nymphs.
Mandli JT, Lee X, Bron GM, Paskewitz SM
Journal of medical entomology. 2021; ():

Infestation. What Is Already Known, and What Is New about Scabies at the Beginning of the Third Decade of the 21st Century?
Talaga-Ćwiertnia K
Pathogens (Basel, Switzerland). 2021; 10(7):

Molecular and functional characterization of three novel carboxylesterases in the detoxification of permethrin in the mosquito, Culex quinquefasciatus.
Gong Y, Li M, Li T, Liu N
Insect science. 2021; ():

Prevalence of in Patients with Suspected scabies.
Yücel A, Yılmaz M
Turkiye parazitolojii dergisi. 2021; 45(2): 133-136

Common pediatric infestations: update on diagnosis and treatment of scabies, head lice, and bed bugs.
Ogbuefi N, Kenner-Bell B
Current opinion in pediatrics. 2021; ():


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.



ScopeMed Web Sites